Neurocrine Q2 revenue $959M (+39% YoY); raises INGREZZA guidance to $2.825-2.875B

NEUROCRINE BIOSCIENCES INC

GAAP EPS $1.39 vs $1.06 YoY; Non-GAAP EPS $2.85 vs $1.65 YoY.
INGREZZA net sales $716M (+15% YoY); full-year guidance raised from $2.7-2.8B to $2.825-2.875B.
CRENESSITY sales $184M (+247% YoY); VYKAT XR contributed $54M from May 18 acquisition close.
Acquired Soleno Therapeutics for $53/share ($2.9B equity value) in May; added VYKAT XR for Prader-Willi syndrome.
Entered $1.0B revolving credit facility; cash & securities $482M (down from $2.543B at year-end due to acquisition).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.